{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:53Z","timestamp":1792636913839,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","award":["RS-2024-00465505"],"award-info":[{"award-number":["RS-2024-00465505"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2023-00242443"],"award-info":[{"award-number":["RS-2023-00242443"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2024-00402899"],"award-info":[{"award-number":["RS-2024-00402899"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2024-00350878"],"award-info":[{"award-number":["RS-2024-00350878"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-02223118"],"award-info":[{"award-number":["RS-2025-02223118"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115039","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:45:03Z","timestamp":1779428703000},"page":"115039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Biomimetic lipid nanoparticles for macrophage reprogramming in cancer immunotherapy"],"prefix":"10.1016","volume":"396","author":[{"given":"Seunghyo","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Dong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Eun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooram","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115039_bb0005","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.devcel.2010.05.012","article-title":"Tumors as organs: complex tissues that interface with the entire organism","volume":"18","author":"Egeblad","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2026.115039_bb0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","article-title":"Improving drug delivery to solid tumors: priming the tumor microenvironment","volume":"201","author":"Khawar","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115039_bb0015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115039_bb0020","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115039_bb0025","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115039_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115039_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115039_bb0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13402-019-00453-z","article-title":"Tumor-associated macrophages: role in cancer development and therapeutic implications","volume":"42","author":"Salmaninejad","year":"2019","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.jconrel.2026.115039_bb0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1189\/jlb.0209073","article-title":"Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages","volume":"86","author":"Stout","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115039_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115039_bb0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.it.2015.02.004","article-title":"Macrophages and cancer: from mechanisms to therapeutic implications","volume":"36","author":"Ostuni","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0095","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","article-title":"Macrophages: the road less traveled, changing anticancer therapy","volume":"24","author":"Guerriero","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115039_bb0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115039_bb0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1564","article-title":"In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses","volume":"27","author":"Kortylewski","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0125","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/0008-5472.CAN-17-1340","article-title":"Roles for innate immunity in combination immunotherapies","volume":"77","author":"Moynihan","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115039_bb0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0135","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1158\/0008-5472.CAN-04-4262","article-title":"Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection","volume":"65","author":"Guiducci","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115039_bb0140","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115039_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0160","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0165","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115039_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115039_bb0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0195","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/cdd.2016.7","article-title":"Exposure of phosphatidylserine on the cell surface","volume":"23","author":"Nagata","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2026.115039_bb0200","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009076","article-title":"Biology of the TAM receptors","volume":"5","author":"Lemke","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0205","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1021\/acs.nanolett.2c03234","article-title":"Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs","volume":"22","author":"Luozhong","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2026.115039_bb0210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2015.09.027","article-title":"Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals","volume":"217","author":"Bagalkot","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115039_bb0215","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115039_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.02.016","article-title":"Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression","volume":"29","author":"Goossens","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2026.115039_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2026.115039_bb0230","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115039_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115039_bb0240","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","article-title":"M2-like tumor-associated macrophage-targeted Codelivery of STAT6 inhibitor and IKKbeta siRNA induces M2-to-M1 repolarization for Cancer immunotherapy with low immune side effects","volume":"6","author":"Xiao","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jconrel.2026.115039_bb0245","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-08-3031","article-title":"Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy","volume":"69","author":"Kortylewski","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115039_bb0250","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1039\/D1BM00531F","article-title":"A nucleic acid nanogel dually bears siRNA and CpG motifs for synergistic tumor immunotherapy","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater Sci-Uk"},{"key":"10.1016\/j.jconrel.2026.115039_bb0255","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.omtn.2021.12.036","article-title":"Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity","volume":"27","author":"Qian","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115039_bb0260","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","article-title":"Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity","volume":"123","author":"Hossain","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115039_bb0265","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.apsb.2024.03.004","article-title":"M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy","volume":"14","author":"Shin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115039_bb0270","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0275","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.2147\/IJN.S430877","article-title":"Advancements in macrophage-targeted drug delivery for effective disease management","volume":"18","author":"Liu","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115039_bb0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2018.01.020","article-title":"Macrophages and lipid metabolism","volume":"330","author":"Remmerie","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0290","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","article-title":"Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages","volume":"148","author":"Fadok","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/727241","article-title":"Targeted liposomal drug delivery to monocytes and macrophages","volume":"2011","author":"Kelly","year":"2011","journal-title":"J. Drug Deliv."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115039_bb0300","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Muller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115039_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114601","article-title":"An inhalable liquid-core lipid nanoplatform enables macrophage-mediated mRNA delivery to lung tumors","volume":"391","author":"Liu","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115039_bb0310","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbrc.2008.03.127","article-title":"Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery","volume":"370","author":"Zhang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115039_bb0315","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115039_bb0320","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115039_bb0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115039_bb0330","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:52:16Z","timestamp":1787579536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0168365926004426"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115039","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomimetic lipid nanoparticles for macrophage reprogramming in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115039"}}